Daniel Antunes Moreno
Overview
Explore the profile of Daniel Antunes Moreno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomaz de Assis E, Ferreira M, de Oliveira J, Mitre L, Correa da Silva E, Salim Coelho L, et al.
World Neurosurg
. 2025 Mar;
:123842.
PMID: 40023279
Purpose: High-grade gliomas (HGG) are aggressive tumors known for their poor prognosis. Despite research into its molecular and clinical aspects, current management minimally impacts survival. It is unclear whether combining...
2.
Cardoso I, Rosa M, Moreno D, Tufi L, Ramos L, Pereira L, et al.
Mol Med Rep
. 2024 Oct;
30(6).
PMID: 39392037
Germ cell tumors (GCTs) constitute diverse neoplasms arising in the gonads or extragonadal locations. Testicular GCTs (TGCTs) are the predominant solid tumors in adolescents and young men. Despite cisplatin serving...
3.
Barateiro L, de Oliveira Cavagna R, Dos Reis M, de Paula F, Teixeira G, Moreno D, et al.
Neuropathology
. 2024 May;
45(1):30-37.
PMID: 38736183
Medulloblastoma (MB) is the most prevalent malignant brain tumor in children, known for its heterogeneity and treatment-associated toxicity, and there is a critical need for new therapeutic targets. We analyzed...
4.
Ferreira M, Thomaz de Assis E, Batista S, Palavani L, Verly G, Correa E, et al.
World Neurosurg
. 2024 Jan;
183:239-245.e2.
PMID: 38184227
Background: Glioblastoma (GBM) is an aggressive tumor known for its poor prognosis. Despite extensive research into its molecular and clinical aspects, the current management strategies have shown limited efficacy in...
5.
Moreno D, Bonatelli M, Antoniazzi A, de Paula F, Leal L, Garcia F, et al.
Front Oncol
. 2023 Sep;
13:1237170.
PMID: 37746264
Purpose: Medulloblastomas are the most common primary malignant brain tumors in children. They are divided into molecular subgroups: WNT-activated, SHH-Activated, mutant or wild type, and non-WNT/non-SHH (Groups 3 and 4)....
6.
de Carvalho L, Komoto T, Moreno D, Goes J, Germano de Oliveira R, de Lima Melo M, et al.
Int J Mol Sci
. 2023 Jun;
24(12).
PMID: 37373211
The aim of this study was to evaluate the expression of , , , and genes in Myelodysplastic neoplasm (MDS) to identify possible targets of ubiquitination and deubiquitination in MDS...
7.
Zantut-Wittmann D, Barreto I, Laus A, Moreno D, Moma C, Maia F, et al.
Mol Cell Endocrinol
. 2023 Apr;
570:111931.
PMID: 37072108
Objectives: MCL-1 and PD-L1 proteins are related to carcinogenesis mechanisms in differentiated thyroid carcinoma(DTC). Tumor antigens stimulate the expression of PD-1 in immune cells, which binds to PD-L1 of tumor...
8.
Ribeiro Junior H, Goncalves P, Moreno D, Goes J, Germano de Oliveira R, Montefusco-Pereira C, et al.
Leuk Res
. 2023 Apr;
129:107071.
PMID: 37004280
Differentially expressed genes (DEGs) biomarkers can be used to help diagnose and monitor the disease, as well as to determine which treatments are most effective. So, given the complexity of...
9.
Garcia F, Evangelista A, Mancano B, Moreno D, Berardinelli G, de Paula F, et al.
Cold Spring Harb Mol Case Stud
. 2023 Mar;
9(1).
PMID: 36963804
Choroid plexus tumors (CPTs) are rare intracranial neoplasms, representing <1% of all brain tumors, yet they represent 20% of first-year pediatric brain tumors. Although these tumors have been linked to...
10.
Marques R, Moreno D, da Silva L, Leal L, de Paula F, Santana I, et al.
Front Immunol
. 2023 Feb;
14:1062856.
PMID: 36825029
Introduction: Medulloblastoma is the most common and lethal pediatric malignant brain tumor. It comprises four main molecular subgroups: WNT-activated, SHH-activated, Group 3, and Group 4. Medulloblastoma treatment is surgical resection,...